Across rheumatic diseases

Prognostic factors for liver, blood and kidney adverse events from glucocorticoid sparing immune-suppressing drugs in immune-mediated inflammatory diseases: a prognostic systematic review

RMD OpenPublished Prognostic systematic review

Authors' conclusion

Prognostic factors for target-organ damage were identified which may be further investigated for their potential role in targeted (risk-stratified) monitoring.

Study context

Population
People receiving glucocorticoid sparing immune-suppressing drugs for IMIDs56 studies from 58 papers
Outcome
Prognostic factors associated with liver, blood or kidney adverse events
Methodological detailsmodified CHARMS-PF checklist, QUIPS risk of bias, GRADE-informed quality of evidence, Excluded: studies published before 1995, with <200 participants, or not in English
  • Modified CHARMS-PF checklist
  • QUIPS risk of bias
  • GRADE-informed quality of evidence
  • Excluded: studies published before 1995, with <200 participants, or not in English

Pooled result

As reported in the abstract

High-quality evidence of prognostic factors
  • Elevated liver enzymes (6 studies): prognostic factor for hepatotoxicity with MTX
  • Folate non-supplementation (3 studies): prognostic factor for hepatotoxicity with MTX
  • Mercaptopurine (vs AZA) (3 studies): prognostic factor for hepatotoxicity with thiopurines
  • Mercaptopurine (vs AZA) (3 studies): prognostic factor for cytopenia with thiopurines
  • Poor-metaboliser status (4 studies): prognostic factor for cytopenia with thiopurines
  • Baseline elevated liver enzymes (3 studies): prognostic factor for hepatotoxicity with anti-TNF

Further pooled results

Moderate and low quality evidence

Several other demographic, lifestyle, comorbidity, baseline bloods/serologic or treatment-related prognostic factors identified

Original publication

Prognostic factors for liver, blood and kidney adverse events from glucocorticoid sparing immune-suppressing drugs in immune-mediated inflammatory diseases: a prognostic systematic review. RMD Open. Published 10 January 2024. doi:10.1136/rmdopen-2023-003588

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.